# Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

Study · id `cardio:ct-nct06668389` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06668389](<https://clinicaltrials.gov/study/NCT06668389>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06668389

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 106 participants.

## Technical summary

Registry record NCT06668389. Randomized; no masking; primary purpose treatment. Start 2025-05-12 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 106 participants (planned count; ClinicalTrials.gov record NCT06668389, source copy `cardio:ctgov-nct06668389-2026-10-28`, retrieved 2026-10-31)
- Started: 2025-05-12 (actual) (ClinicalTrials.gov record NCT06668389, source copy `cardio:ctgov-nct06668389-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06668389, source copy `cardio:ctgov-nct06668389-2026-10-28`, retrieved 2026-10-31)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06668389, source copy `cardio:ctgov-nct06668389-2026-10-28`, retrieved 2026-10-31)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT06668389, source copy `cardio:ctgov-nct06668389-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06668389-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
- Acronym: STEPS
- Condition: Congenital Heart Disease
- Condition: Repaired Tetralogy of Fallot (rTOF)
- Condition: Pulmonary Regurgitation
- Condition: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitor
- Condition: Dapagliflozin (Forxiga)
- Intervention (Drug): SGLT2 inhibitor (Dapagliflozin 10mg)
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Adult congenital heart disease (`cardio:adult-congenital-heart-disease`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)

## Provenance

Content hash: 2d0e2f3c6d9ae59b1e4cb28bdf64e14bd221edfc8893c099bbe649d5cce22ee6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
